Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
about
Regional control and morbidity after superficial groin dissection in melanomaSurgical resection for bulky or recurrent axillary metastatic melanoma.Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma siteUnexpected Long Survival in Primary Malignant Melanoma of the Male Urethra.Weight lifting in patients with lower-extremity lymphedema secondary to cancer: a pilot and feasibility study.Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection.Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumourManagement of regional lymph node basins in melanoma.Effect of single-walled carbon nanotubes on tumor cells viability and formation of multicellular tumor spheroids.Therapeutic lymph node dissection in melanoma: different prognosis for different macrometastasis sites?Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors.Cutaneous head and neck melanoma: the old and the new.Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.Lymph node assessment in melanomaMorbidity After Inguinal Lymph Node Dissections: It Is Time for a ChangeInitial experience with videoscopic inguinal lymphadenectomy.Axillary lymph node dissection for malignant melanoma.How often do level III nodes bear melanoma metastases and does it affect patient outcomes?Videoscopic inguinal lymphadenectomy for metastatic melanoma.Sentinel lymph node biopsy for eyelid and conjunctival tumors: what is the evidence?A Minimally Invasive Approach for Inguinal Lymphadenectomy in Melanoma and Genitourinary Malignancy: Long-Term Outcomes in an Attempted Randomized Control Trial.Is the non-sentinel lymph node compartment the next site for melanoma progression from the sentinel lymph node compartment in the regional nodal basin?Dendritic cell vaccination in melanoma patients: From promising results to future perspectivesAssessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma.Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases.BAG3 protein expression in melanoma metastatic lymph nodes correlates with patients' survival.Minimally invasive inguinal lymph node dissection (MILND) for melanoma: experience from two academic centers.Outcome of clinical stage III melanoma patients with FDG-PET and whole-body CT added to the diagnostic workup.Quadriceps keystone island flap for radical inguinal lymphadenectomy: a reliable locoregional island flap for large groin defects.Robot-assisted video endoscopic inguinal lymphadenectomy for melanoma.5th Canadian Melanoma Conference: research frontiers.An unusual complication of axillary lymph-node clearance.
P2860
Q30356674-85DFC16F-FAD9-470D-8208-1BA7E9D45086Q30384788-06878DC1-9B7E-44FE-A0B8-D71F95E9881EQ33911465-792F64E4-4A74-4C30-BC2D-EAF74F1EA1CCQ33953698-4482323B-D4C3-4363-BBFA-A274FC332168Q33964824-5B00C910-25EC-41EE-9C2B-67BAF80E0662Q34409481-7D44C79C-C0FA-4F15-A139-A64E2C21CD96Q34794495-F6109641-CE28-4976-95D8-47D8C7CDA00DQ34986232-93B506CB-EDAB-4340-B482-F5B51CEC01A6Q35267717-079154E4-6A72-4A72-88C9-D3DBC3CFB539Q36339446-97C3B40D-89D9-4A77-9022-3E697A28EFA3Q36597517-5F70120D-11F7-47B0-AB08-216C138BC6DAQ36648843-53BA1EFF-08AA-44F0-8C06-1A280C8400A4Q37118944-61F7870F-527D-4983-858A-5C51892E4DACQ37216415-C926AE4B-7DBD-435C-B12B-D99BA5C929AFQ37222157-A8F98325-7119-4EA1-B126-7F31F8100F34Q37344300-8D27CBD7-593A-4CB9-B628-F761E22E0423Q37560343-A932D625-5CFB-4E16-AD83-9935AED9B6CBQ37823856-2AF6AECE-AEE9-4683-AFE4-650167212837Q37980464-EEEEFFD9-D268-4F32-95CB-36AA4A851CD7Q38078224-6F312193-5F6A-41E7-B2A9-13BE8B82907FQ38146705-A019D6E2-45FD-40E9-AF6F-E32279A642BDQ38273044-BF27C600-1787-45A0-9DF3-ABF87DB593BBQ38645134-2EB53DA5-1CD0-413B-B3BF-79F4774A70D4Q38683103-9E4A5589-BA7A-4DA3-B1EE-3FA68B4D3F98Q38850950-E4EDA5D8-A834-44E9-B54D-9FDC750935BBQ38877852-579E76E0-05F7-477E-BA71-643F91A14674Q40922293-0C8B7A10-60DD-41FE-A8B7-AD313037E8A3Q42353188-762EE0CA-5C0F-40CA-82A7-4F4A66E1F851Q42662523-2B0D85CC-7359-479D-864E-5DB1F5F81A5AQ43705084-77A07AAB-403D-424D-99EC-14E2A1F14CDDQ44309097-F5243729-0F30-49F4-9BE9-F6CF63219480Q46873092-31C6BF41-1ACB-4F0F-8BEA-BF5DC89270C5Q47583512-586022E0-2D49-48CA-BFB6-18FFF9F7E23AQ50495385-B458738C-C281-442E-A355-890EA77DCC53
P2860
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
@ast
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
@en
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
@nl
type
label
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
@ast
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
@en
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
@nl
prefLabel
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
@ast
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
@en
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma.
@nl
P2093
P1476
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma
@en
P2093
Bouwhuis MG
Eggermont AM
Grunhagen DJ
Hoedemaker R
Schmitz PI
de Wilt JH
van Geel AN
P304
P356
10.1016/J.EJSO.2006.10.032
P577
2006-12-11T00:00:00Z